Vanda jumps after FDA reviewers back tasimelteon

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) jumped $6.51 (96%) to $13.30 on Tuesday after FDA reviewers recommended approval of the company's Hetlioz tasimelteon ( VEC-162) to treat non-24-hour sleep wak...